© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > AZD0364
<< Back to December
oral reversible ERK1/2 kinase inhibitor
combo eff. w/ MEKi in mKRAS model; in Ph. I
from historical kinase sel. data, SBDD + opt.
Mol. Cancer Ther. Dec. 3, 2020
AstraZeneca, Cambridge, UK
AstraZeneca oral reversible ERK1/2 kinase inhibitor
Unlock this content with a Premium membership to read it now.